https://www.selleckchem.com/products/at13387.html
BACKGROUND Atrial septal defect (ASD) is one of the most common congenital heart diseases. Percutaneous closure is the preferred treatment, but certain complications remain a concern. The most common devices are AMPLATZER™ (ASO) (St. Jude Medical, St. Paul, MN, USA) and Figulla Flex® septal occluders (FSO) (Occlutech GmbH, Jena, Germany). The present study aimed to assess main differences in outcomes. METHODS A systematic search in Pubmed and Google scholarship was performed by two independent reviewers for any study comparing ASO and F
Like
Comment
Share
